GW406381
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H526879

CAS#: 221148-46-5

Description: GW406381 is a novel COX-2 inhibitor as a potential treatment for acute migraine. GW406381 is highly selective cyclooxygenase-2 (COX-2) inhibitor that is effective in animal models of central sensitization and of inflammatory pain. GW406381 attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. GW406381 is effective in animal models of neuropathic pain and central sensitization.


Chemical Structure

img
GW406381
CAS# 221148-46-5

Theoretical Analysis

Hodoodo Cat#: H526879
Name: GW406381
CAS#: 221148-46-5
Chemical Formula: C21H19N3O3S
Exact Mass: 393.11
Molecular Weight: 393.461
Elemental Analysis: C, 64.11; H, 4.87; N, 10.68; O, 12.20; S, 8.15

Price and Availability

Size Price Availability Quantity
5mg USD 350 2 Weeks
10mg USD 650 2 Weeks
25mg USD 1070 2 Weeks
Bulk inquiry

Synonym: GW-406381; GW 406381; GW406381;

IUPAC/Chemical Name: 2-(4-ethoxyphenyl)-3-(4-(methylsulfonyl)phenyl)pyrazolo[1,5-b]pyridazine

InChi Key: NXMZBNYLCVTRGB-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3

SMILES Code: O=S(C1=CC=C(C2=C3C=CC=NN3N=C2C4=CC=C(OCC)C=C4)C=C1)(C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO, sonicated 25.0 63.00

Preparing Stock Solutions

The following data is based on the product molecular weight 393.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Moore RA, Chi CC, Wiffen PJ, Derry S, Rice AS. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev. 2015 Oct 5;(10):CD010902. doi: 10.1002/14651858.CD010902.pub2. Review. PubMed PMID: 26436601.

2: Taneja A, Oosterholt SP, Danhof M, Della Pasqua O. Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor. J Clin Pharmacol. 2016 May;56(5):609-21. doi: 10.1002/jcph.629. Epub 2015 Dec 27. PubMed PMID: 26331692.

3: Wilkinson MC. "Greener" Friedel-Crafts acylations: a metal- and halogen-free methodology. Org Lett. 2011 May 6;13(9):2232-5. doi: 10.1021/ol200482s. Epub 2011 Mar 25. PubMed PMID: 21438589.

4: Varner J, Lomax M, Blum D, Quessy S. A randomized, controlled, dose-ranging study investigating single doses of GW406381, naproxen sodium, or placebo in patients with acute pain after third molar tooth extraction. Clin J Pain. 2009 Sep;25(7):577-83. doi: 10.1097/AJP.0b013e3181a085fa. PubMed PMID: 19692798.

5: Shackelford S, Rauck R, Quessy S, Blum D, Hodge R, Philipson R. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia. J Pain. 2009 Jun;10(6):654-60. doi: 10.1016/j.jpain.2009.01.328. Epub 2009 May 5. PubMed PMID: 19409858.

6: Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, Quessy SN. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape J Med. 2008;10(11):259. Epub 2008 Nov 12. PubMed PMID: 19099009; PubMed Central PMCID: PMC2605121.

7: Wentz AL, Jimenez TB, Dixon RM, Aurora SK, Gold M; CXA20008 Study Investigators. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine. Eur J Neurol. 2008 Apr;15(4):420-7. doi: 10.1111/j.1468-1331.2008.02093.x. Epub 2008 Feb 26. PubMed PMID: 18312401.

8: Zhao FY, Spanswick D, Martindale JC, Reeve AJ, Chessell IP. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. Pain. 2007 Mar;128(1-2):78-87. Epub 2006 Oct 19. PubMed PMID: 17055166.

9: Bingham S, Beswick PJ, Bountra C, Brown T, Campbell IB, Chessell IP, Clayton N, Collins SD, Davey PT, Goodland H, Gray N, Haslam C, Hatcher JP, Hunter AJ, Lucas F, Murkitt G, Naylor A, Pickup E, Sargent B, Summerfield SG, Stevens A, Stratton SC, Wiseman J. The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther. 2005 Mar;312(3):1161-9. Epub 2004 Nov 30. PubMed PMID: 15572651.

10: Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J. Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5445-8. PubMed PMID: 15454242.

11: Sertsou G, Butler J, Scott A, Hempenstall J, Rades T. Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int J Pharm. 2002 Oct 1;245(1-2):99-108. PubMed PMID: 12270247.